51301-86-1

Basic information

• Product Name: 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID
• Synonyms: BOC-DL-4-CHLOROPHENYLALANINE;2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID;Boc-4-Chloro-DL-Phenylalanine;Boc-DL-Phe(4-Cl)-OH;N-(tert-Butoxycarbonyl)-4-chloro-DL-phenylalanine;2-BOC-AMINO-3-(4-CHLORO-PHENYL)-PROPANOIC ACID
• CAS NO: 51301-86-1
• Molecular Formula: C₁₄H₁₈ClNO₄
• Molecular Weight: 299.75
• Mol File: 51301-86-1.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID(51301-86-1)
• EPA Substance Registry System: 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID(51301-86-1)

Safety Data

• Hazardous Substances Data: 51301-86-1(Hazardous Substances Data)

Usage

Description

2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID is a chemical compound characterized by its unique molecular structure, which features a tert-butoxycarbonyl group, an amino group, a 4-chlorophenyl group, and a propionic acid moiety. 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID is known for its distinct properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID is used as an analyte in the enantiomeric separation process for pharmaceutical applications. 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID plays a crucial role in the development and analysis of chiral drugs, which are essential in the pharmaceutical industry due to their different biological activities and potential therapeutic benefits.
Used in Analytical Chemistry:
In the field of analytical chemistry, 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID is utilized as an analyte for enantiomeric separation by High-Performance Liquid Chromatography (HPLC). This technique is vital for determining the purity and enantiomeric composition of chiral compounds, which is essential for understanding their properties and potential applications.
Used in Chiral Stationary Phase Development:
2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID is also used in the development of chiral stationary phases for HPLC. 2-TERT-BUTOXYCARBONYLAMINO-3-(4-CHLORO-PHENYL)-PROPIONIC ACID's interaction with covalently bonded macrocyclic antibiotic ristocetin A as a chiral stationary phase helps in the separation of enantiomers, which is a critical aspect of chiral chromatography and has significant implications in various industries, including pharmaceuticals, agrochemicals, and environmental science.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7424-00-2 DL-Phe(4Cl) 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 14173-39-8 p-chlorophenylalanine 
• 159750-06-8 (4S,2S)-4-Chloro-<2-<<(1,1-dimethylethoxy)carbonyl>amino>-3-oxo-3-<2-oxo-4-(phenylmethyl)-3-oxazolidinyl>propyl>benzene 
• 159750-02-4 (4S,2S)-4-Chloro-<2-azido-3-oxo-3-<2-oxo-4-(phenylmethyl)-3-oxazolidinyl>propyl>benzene 
• 2019-34-3 3-(4-chlorophenyl)propanoic acid 
• 1615-02-7 3-(4-chlorophenyl)prop-2-enoic acid 
• 1027659-22-8 C₁₄H₁₇ClO₃ 
• 159750-01-3 (4S)-4-Chloro-<3-oxo-3-<2-oxo-4-(phenylmethyl)-3-oxazolidinyl>propyl>benzene 
• 77-92-9 citric acid 
• 35448-10-3 oxalic acid mono-tert-butyl ester 
• 68759-85-3 para-chlorophenylalanine methyl ester 

Downstream Products

• 159750-10-4 N-<(1,1-Dimethylethoxy)carbonyl>-4-chloro-L-phenylaanine 2-iodoethyl ester 
• 139377-29-0 D,L-N-<(1,1-dimethylethoxy)carbonyl>-4-chlorophenylalanine 2-(trimethylsilyl)ethyl ester 
• 139377-31-4 D,L-N-<(1,1-dimethylethoxy)carbonyl>-4-chlorophenylalanine pentafluorophenyl ester 
• 74105-22-9 t-butyloxycarbonyl-4-chlorophenylalanyl-serine methyl ester 
• 119744-86-4 tert-butyl (S)-[1-amino-3-(4-chlorophenyl)-1-oxopropan-2-yl]carbamate 
• 84796-24-7 tert-butyloxycarbonyl-p-chlorophenylalanyl-isoleucyl-glutaminyl-asparaginyl-S-(β-carboxyethyl)homocysteinyl-prolyl-leucyl-glycine amide 
• 139377-30-3 D,L-N-<(1,1-dimethylethoxy)carbonyl>-4-chlorophenylalanine 2-bromoethyl ester 
• 159750-09-1 N-<(1,1-Dimethylethoxy)carbonyl>-4-chloro-L-phenylalanine 2-bromoethyl ester 
• 172035-51-7 (9S,12S,15S)-12-Benzyl-15-tert-butoxycarbonylamino-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carboxylic acid methyl ester 
• 251308-34-6 [[2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionyl]-(3-phenyl-propyl)-amino]-acetic acid methyl ester 
• 475095-00-2 [1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS

Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis

Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are the enzymatically active chitinases that have been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis. The clinical and preclinical data suggest that pharmacological inhibition of CHIT1 might represent a novel therapeutic approach in IPF. Structural modification of an advanced lead molecule 3 led to the identification of compound 9 (OATD-01), a highly active CHIT1 inhibitor with both an excellent PK profile in multiple species and selectivity against a panel of other off-targets. OATD-01 given orally once daily in a range of doses between 30 and 100 mg/kg showed significant antifibrotic efficacy in an animal model of bleomycin-induced pulmonary fibrosis. OATD-01 is the first-in-class CHIT1 inhibitor, currently completed phase 1b of clinical trials, to be a potential treatment for IPF.

Synthesis of an amidosulfonate-tagged biphenyl phosphine and its application in the Suzuki-Miyaura reaction affording biphenyl-substituted amino acids in water

An amidosulfonate-tagged phosphinobiphenyl, viz triethylammonium 2-(dicyclohexylphosphino)-4′-{[(sulfonatomethyl)amino]carbonyl}biphenyl (3), was prepared in two steps from 2-(dicyclohexylphosphino)biphenyl-4′-carboxylic acid and fully characterized including the crystal structure determination. As a highly polar phosphine ligand, compound 3 was employed in the Pd-catalyzed Suzuki-Miyaura cross-coupling of N-Boc protected 4-bromo and 4-chlorophenylalanine with aromatic boronic acids to afford the corresponding biphenyls in aqueous N,N-dimethylformamide or pure water. The coupling was demonstrated to proceed very well and without the loss of the Boc protecting group when the bromo-substituted substrate is reacted in the presence of 1 mol.% of Pd/3 catalyst in water at 40 °C. Reactions with boronic acids bearing electron-withdrawing substituents and, mainly, those with the less reactive chlorophenylalanine substrate required slightly higher reaction temperature and more catalyst to achieve similar results.